Meeting
2018 ASCO Annual Meeting
Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.
Authors
Adil Daud
University of California, San Francisco, San Francisco, CA
Adil Daud , Mansoor N. Saleh , James Hu , Jonathan Scott Bleeker , Matthew John Riese , Roland Meier , Li Zhou , Gul Serbest , Karl D. Lewis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02327078
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9511)
DOI
10.1200/JCO.2018.36.15_suppl.9511
Abstract #
9511
Poster Bd #
338
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
PEMBROSARC combination of MK3475 and metronomic cyclophosphamide (mCP) in patients (pts) with advanced sarcomas a multicentre phase II trial with 3 new combination strategies.
First Author: Maud Toulmonde
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.
First Author: Ning Li
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok